FDA-Approved MedicationUpdated November 2026

Ozempic Guide

Ozempic is the brand-name formulation of semaglutide FDA-approved for type 2 diabetes management, though it has become widely prescribed off-label for weight loss. It is available in doses of 0.5mg, 1mg, and 2mg weekly, and is manufactured by Novo Nordisk. Ozempic also carries FDA indications to reduce cardiovascular risk in adults with type 2 diabetes and heart disease, and to reduce the risk of kidney disease progression and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

At a Glance

Generic NameSemaglutide
Brand NamesOzempic
FDA StatusFDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020); FDA-approved to reduce the risk of kidney disease progression and cardiovascular death in adults with T2DM and chronic kidney disease. Weight loss is off-label use.[1]
Approval DateDecember 5, 2017[1]

How Ozempic Works

Ozempic activates GLP-1 receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, and reduce blood sugar levels. The same mechanism that controls blood glucose also suppresses appetite and slows gastric emptying, producing significant weight loss as a secondary effect. At 1–2mg doses, Ozempic delivers strong appetite suppression comparable to Wegovy's lower dose range.[2][3]

Dosing Schedule

Ozempic uses a gradual dose escalation to minimize side effects. Always follow your prescriber's guidance and the current FDA label[1].

Weeks 1–40.25mg/week
Weeks 5+0.5mg/week
After 4+ weeks at 0.5mg1mg/week (if needed)
After 4+ weeks at 1mg2mg/week (max)

Side Effects

Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.[1][2]

This is not a complete list. Consult your healthcare provider or prescriber for full safety information. The complete adverse reaction profile is published in the current FDA prescribing information[1].

Clinical Trial Results

In the SUSTAIN-6 cardiovascular trial, Ozempic reduced the risk of major cardiovascular events by 26% vs. placebo (Marso et al. NEJM 2016, PMID 27633186). For weight loss specifically, the STEP-8 head-to-head trial (Rubino et al. JAMA 2022, PMID 34962517) used semaglutide 2.4 mg — the Wegovy dose, not the Ozempic 1 mg dose — and showed 15.8% weight loss vs 6.4% for liraglutide 3 mg. Ozempic itself is FDA-approved only for type 2 diabetes; Wegovy is the FDA-approved semaglutide for chronic weight management.[2]

Source: Published clinical trial data (STEP / SURMOUNT trial series) — see the Sources panel below for full citations.

Where to Get Ozempic

These telehealth providers offer access to semaglutide with online consultations and home delivery. Before you book a consult, our guide to getting Ozempic online walks through eligibility, the prescriber visit, and what legitimate pharmacy fulfillment looks like.

8.2/ 10
Partner

Gala

Best for: compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

★★★★☆4.1/5

Editorial score · methodology

$129/mosemaglutide
starting dose
$179/motirzepatide
prepaid plan rate
CompoundedSemaglutideTirzepatideLegitScript Verified
Get StartedRead full Gala review →
8.1/ 10
Partner

RxSpan MD

Best for: physician-led, pharmacy-transparent compounded GLP-1 with brand-name options

★★★★☆4.1/5

Editorial score · methodology

$249/mosemaglutide
$329/motirzepatide
CompoundedSemaglutideTirzepatideGHK-CuGlutathioneLegitScript Verified
Get StartedRead full RxSpan MD review →
8.0/ 10
Partner

Sesame Care

Best for: Brand-name GLP-1s at cash prices, no compounding

★★★★☆4/5

Editorial score · methodology

$149/mosemaglutide
see plan details
BrandSemaglutideTirzepatideOrforglipron
Get StartedRead full Sesame Care review →
7.6/ 10
Partner

Maximus

Best for: men seeking compounded tirzepatide alongside testosterone optimization

★★★★☆3.8/5

Editorial score · methodology

$100/mosemaglutide
microdose plan
$100/motirzepatide
12-month plan rate
CompoundedSemaglutideTirzepatideOrforglipronSermorelinFDA Warning
Get StartedRead full Maximus review →
7.6/ 10
Partner

SkinnyRx

Best for: compounded semaglutide or tirzepatide with the consult and free overnight shipping in one price

★★★★☆3.8/5

Editorial score · methodology

$99/mosemaglutide
intro price
$299/motirzepatide
after intro offer
CompoundedSemaglutideTirzepatideOrforglipronSermorelinFDA Warning
Get StartedRead full SkinnyRx review →
7.5/ 10
Partner

Luvo Health

Best for: compounded and brand GLP-1s, oral tablets and microdosing on one public price list

★★★★☆3.8/5

Editorial score · methodology

$209/4 wkssemaglutide
billed per 4 weeks
$249/4 wkstirzepatide
billed per 4 weeks
CompoundedSemaglutideTirzepatideGonadorelinNAD+LegitScript Verified
Get StartedRead full Luvo Health review →

Each provider's lowest ongoing monthly cash price for Ozempic, sorted cheapest first (no copays, membership fees or intro offers). Both compounded and brand-name prescriptions are generally FSA/HSA eligible under IRS Publication 502[6]. Prices may vary based on dose.

ProviderFrom (ongoing)
Hers$149/mo+ required membershipVisit
Hims$149/mo+ required membershipVisit
NovoCare Pharmacy$149/morises with doseVisit
GOAL.MD$294/mosee plan detailsVisit
Sesame Care$349/moafter intro offerVisit
Maximus$350/mostarting doseVisit
WePeptideRx$429/moper 4 weeksVisit
Care Bare Rx$705/mo“starting at” priceVisit
Vital Edge$705/moVisit
altRX$1,149/moVisit
Medsol RX$1,229/mosee plan detailsVisit
Aquivia Health$1,299/mosee plan detailsVisit
Gala$1,299/moentry-tier priceVisit
Luvo Health$1,299/moper 4 weeksVisit
Meant$1,299/moentry-tier priceVisit
Pallas Health$1,299/mosee plan detailsVisit
RxSpan MD$1,299/moVisit
Trimrose$1,299/mostarting doseVisit
Tryozi$1,299/moVisit
Effecty$1,300/mosee plan detailsVisit
Bon Health$1,319/mo+ added feeVisit
Elevated Health$1,399/mo“starting at” priceVisit
Livbetr$1,399/moVisit
SkinnyRx$1,400/mosee plan detailsVisit
myRocky$1,409/moVisit
Fridays$1,498/moVisit
NuuVim$1,498/mostarting doseVisit
Corsica Health$1,499/mosee plan detailsVisit
Layla$1,499/moafter intro offerVisit
Good Girl Rx$1,580/moVisit
DudeMeds$1,585/mo3-month plan rateVisit
Concierge MD LA$1,999/moVisit

Short-form verdict pages comparing Ozempic to other GLP-1 options with trial-anchored data, FDA-label dosing, and current manufacturer pricing.

See all drug-vs-drug verdicts, or compare every weight loss medication we cover.

Endpoint-by-endpoint breakdowns of the trials that shaped the Ozempic label, with primary-source numbers and FAQs.

SUSTAIN-6
SUSTAIN-6 (Marso 2016, NEJM, PMID 27633186) is the cardiovascular-outcomes trial that earned semaglutide its FDA cardioprotection labeling for Ozempic. Across 3,297 adults with type 2 diabetes at high cardiovascular risk, weekly subcutaneous semaglutide (pooled 0.5 mg and 1.0 mg) reduced the three-point MACE composite by 26% versus placebo over a median 104 weeks. The MACE win was driven primarily by a 39% reduction in nonfatal stroke and a 26% directional reduction in nonfatal myocardial infarction; cardiovascular death and all-cause mortality were unchanged. Lower rates of new or worsening nephropathy stood alongside a notable safety signal: diabetic retinopathy complications were 76% more frequent on semaglutide, the trade-off that has shaped every semaglutide CVOT discussion since.
Phase 3 · N=3,297 · Last verified November 2026
FLOW
FLOW (Perkovic 2024, NEJM, PMID 38785209) is the first GLP-1 receptor agonist trial designed and powered for a primary kidney outcome. The trial randomized 3,533 adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide 1.0 mg or placebo and was halted early for efficacy after a planned interim analysis. Over a median 3.4 years of follow-up, semaglutide reduced the primary composite of major kidney-disease events and cardiovascular or kidney death by 24% versus placebo. The result drove the January 2025 FDA Ozempic label expansion for reducing the risk of kidney-disease progression and kidney failure in adults with type 2 diabetes and chronic kidney disease.
Phase 3b · N=3,533 · Last verified November 2026
SUSTAIN-7
SUSTAIN-7 (Pratley 2018 Lancet Diabetes Endocrinol, PMID 29397376) is the first registrational head-to-head trial of two once-weekly GLP-1 receptor agonists. Novo Nordisk randomized 1,201 adults with type 2 diabetes inadequately controlled on metformin 1:1:1:1 to once-weekly subcutaneous semaglutide 0.5 mg, dulaglutide 0.75 mg, semaglutide 1.0 mg, or dulaglutide 1.5 mg for 40 weeks in an open-label design. At both the low-dose and high-dose comparisons, semaglutide cut HbA1c roughly 0.4 percentage points more than dulaglutide and reduced body weight by an additional 2.3 to 3.5 kg, with broadly similar gastrointestinal tolerability. The trial provided the regulatory and clinical basis for positioning semaglutide as the strongest A1C-reducing GLP-1 in the class.
Phase 3b · N=1,201 · Last verified November 2026

Real patient questions about Ozempic pulled from named subreddits and answered with peer-reviewed trial data.

Scannable cheat sheets for dose schedules, missed-dose rules, and red-flag side effects — every number verified against the DailyMed FDA label.

Curated lists of the highest-impact peer-reviewed studies on Ozempic and related GLP-1 drugs. Every PMID is checked against its PubMed record.

Top 10 PubMed Studies on Semaglutide for Weight Loss (2026)
Ten peer-reviewed semaglutide weight-loss studies anchored to the STEP program (STEP-1 to STEP-8, STEP-TEENS, STEP-HFpEF), the SELECT cardiovascular outcomes trial, and OASIS-1 high-dose oral. Each entry includes the PMID, trial design, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on GLP-1 Cardiovascular Outcomes (2026)
Ten landmark cardiovascular outcomes trials that established GLP-1 receptor agonists as cardioprotective drugs beyond glycemic control. Covers MACE reduction in type 2 diabetes (LEADER, SUSTAIN-6, REWIND, AMPLITUDE-O, PIONEER 6), the SURPASS-CVOT tirzepatide-versus-dulaglutide trial, the SELECT paradigm-shift in obesity without diabetes, kidney outcomes in FLOW, heart failure in STEP-HFpEF, and the foundational neutral ELIXA post-ACS trial. Each entry includes the PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on GLP-1 Receptor Agonists for Kidney Disease (2026)
Ten peer-reviewed studies that built the kidney-outcomes case for GLP-1 receptor agonists. FLOW (2024) is the only dedicated CKD pivotal trial and drove the January 2025 FDA kidney label for Ozempic. The other nine are renal-endpoint analyses from major cardiovascular outcomes trials (LEADER, REWIND, SUSTAIN-6, AMPLITUDE-O, ELIXA, SURPASS-4), the AWARD-7 dedicated moderate-to-severe CKD trial in dulaglutide, the FLOW SGLT2 interaction analysis, and a Lancet class-level meta-analysis. Each entry includes PMID, NCT, primary endpoint, and editorial summary.
10 ranked papers · Last verified November 2026
Top 10 PubMed Studies on Compounded GLP-1 Safety and Quality (2026)
Ten peer-reviewed papers that document the safety, quality, and regulatory landscape of compounded GLP-1 receptor agonists. No published head-to-head bioequivalence randomized trial has compared compounded semaglutide or tirzepatide against brand-name Wegovy, Ozempic, Mounjaro, or Zepbound. The literature instead consists of FAERS and EudraVigilance pharmacovigilance studies, poison-control case series, mass-spectrometry impurity analyses, an FDA-shortage 503A-vs-503B regulatory review, the 2025 American Diabetes Association statement, a direct-to-consumer market analysis, and clinical-guidance reviews. Each entry includes PMID, source journal, study design, and editorial summary explaining what the paper documents and what it does not establish.
10 ranked papers · Last verified November 2026

Deep-dive articles from our research desk with primary-source trial data, FDA label verification, and editorial analysis.

Switching From Semaglutide to Tirzepatide: Washout, Dose & What to Expect (2026)
Switching from semaglutide to tirzepatide: the short 3-7 day timing gap, why you restart at 2.5 mg (no dose-matching, no conversion chart), and what to expect. Prescriber-led.
9 min read6 citations
How to Inject Semaglutide: A Step-by-Step Guide (Sites, Technique & Mistakes to Avoid) (2026)
How to inject semaglutide step by step: prefilled pen vs compounded vial, injection sites, rotation, the right angle and technique, sharps disposal, and mistakes to avoid.
8 min read4 citations
Best Time of Day to Take Semaglutide: Morning or Night? (2026)
Injectable semaglutide (Ozempic, Wegovy) can be taken any time of day, with or without food — same day each week is what matters. Rybelsus is the strict morning exception.
6 min read5 citations
What 3 Ingredients Mimic Ozempic? (Honest Answer: None Do) (2026)
No combination of 3 ingredients mimics Ozempic. We grade berberine, soluble fiber (oatzempic), and apple cider vinegar honestly against semaglutide's ~15% weight loss.
9 min read5 citations
Do You Need Labs for Semaglutide? Bloodwork Before & During Treatment (2026)
Semaglutide has no FDA-label requirement for routine lab monitoring, but baseline bloodwork is strongly advisable. What labs, why, how often, and getting it without labs.
9 min read5 citations
Why Do So Many People Quit Ozempic? The Real Reasons (2026)
Most people quit Ozempic within a year. The real reasons — GI side effects, $1,000+/mo cost, plateaus, regain fear — and what to do instead of quitting. Real-world evidence, not anecdotes.
9 min read4 citations

Frequently Asked Questions

FDA-approved for glycemic control in type 2 diabetes (December 2017); FDA-approved to reduce cardiovascular risk in adults with T2DM and established CVD (2020); FDA-approved to reduce the risk of kidney disease progression and cardiovascular death in adults with T2DM and chronic kidney disease. Weight loss is off-label use.
Among the 32 providers in the cost comparison table above, Ozempic's lowest ongoing monthly cash price is $149 and the highest is $1,999, depending on provider, form and dose. These are medication prices only — copays, membership fees and intro offers are excluded. Always check for manufacturer savings programs.
Common: nausea, vomiting, diarrhea, stomach pain, constipation. Injection site reactions are common in early weeks. Serious (rare): pancreatitis, diabetic retinopathy worsening, kidney injury, hypoglycemia when combined with sulfonylureas or insulin. Thyroid C-cell tumor risk noted in animal studies.
Ozempic requires a prescription from a licensed healthcare provider. You can get it through your primary care doctor, endocrinologist, or a telehealth platform. The telehealth providers listed above prescribe it online.
Sources & methodology (as of November 2026)
  1. 1.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  2. 2.SUSTAIN-6 Trial — Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (Marso SP et al.)— New England Journal of Medicine.PMID: 27633186.
  3. 3.ADA — Standards of Care in Diabetes (2025)— American Diabetes Association.
  4. 4.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  5. 5.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  6. 6.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Key terms, explained

New to GLP-1s? Tap any term for a quick, plain-English definition.